Evaluation of bone markers in hypophosphatemic rickets/osteomalacia.

Endocrine (2011-08-09)
Yuki Nagata, Yasuo Imanishi, Akira Ishii, Masafumi Kurajoh, Koka Motoyama, Tomoaki Morioka, Hiroshi Naka, Katsuhito Mori, Takami Miki, Masanori Emoto, Masaaki Inaba

N-terminal propeptide of type I procollagen (PINP) is a marker of newly formed type I collagen. However, its role in hypophosphatemic rickets/osteomalacia has not yet been established. Metabolic bone markers were examined in patients with oncogenic osteomalacia (OOM) and X-linked hypophosphatemic rickets (XLH), and in healthy controls. OOM and XLH patients were found to have hypophosphatemia secondary to elevated levels of serum fibroblast growth factor 23 (FGF-23). OOM patients had reduced levels of 1,25-dihydroxy vitamin D (1,25D) compared with XLH patients and healthy controls, despite attenuation of the reduction in these levels in the XLH patients secondary to active vitamin D supplementation. In contrast to patients with XLH, OOM patients showed a significant increase in serum PINP, which is suggestive of accelerated bone matrix formation. Bone alkaline phosphatase (BAP) and the BAP/PINP ratio were also increased in OOM but not in XLH patients, suggesting the presence of a disturbance in bone mineralization in OOM. Long-term supplementation of active form vitamin D and inorganic phosphate (IP) may have attenuated the defect in bone mineralization in the XLH patients, resulting in the normalization of PINP, BAP, and the BAP/PINP ratio. The present results suggest that, as with BAP, PINP is an appropriate metabolic bone marker in the assessment of hypophosphatemic rickets/osteomalacia.


1α,25-二羟基维生素D2标准液 溶液, 5 μg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
1α,25-二羟维生素 D2, ≥97.0% (sum of vitamin and previtamin, HPLC)